Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Dermatologic 2Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Breast Neoplasms 5Prostatic Neoplasms 4Melanoma 2Lymphoma, Non-Hodgkin 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Sarcoma, Ewing 1Ovarian Neoplasms 1Osteosarcoma 1Osteoporosis 1Neuroblastoma 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Hodgkin Disease 1Hepatoblastoma 1Hematopoietic and Lymphoid System Neoplasm 1Endometrial Neoplasms 1Desmoid Tumors 1Colorectal Neoplasms 1Clinical Stage III Cutaneous Melanoma AJCC v8 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 137Nivolumab 116Ipilimumab 68Cyclophosphamide 33Specimen Handling 31Magnetic Resonance Spectroscopy 28trametinib 23binimetinib 22fludarabine 21Interleukin-2 20dabrafenib 19relatlimab 17encorafenib 17Biopsy 17CTLA-4 Antigen 16cemiplimab 15atezolizumab 15aldesleukin 15Radiosurgery 15fludarabine phosphate 14Opdualag 14Radiotherapy 11lenvatinib 10Blood Specimen Collection 10lifileucel 9Paclitaxel 8Cisplatin 8Bevacizumab 8spartalizumab 7cobimetinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Absorptiometry, Photon × 1 year × Clear all
NCT07555210 2026-05-06

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Vanderbilt-Ingram Cancer Center

Phase NA Recruiting
25 enrolled
BreastDermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma, Triple Negative Breast Neoplasms

NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡